

Pierre Baumann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5388593/publications.pdf>

Version: 2024-02-01

282
papers

11,175
citations

23567

58
h-index

38395

95
g-index

327
all docs

327
docs citations

327
times ranked

6575
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacotherapy of Personality Disorders. , 2022, , 1-18.		0
2	Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. Therapeutic Drug Monitoring, 2021, 43, 79-102.	2.0	23
3	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) Tj ETQq1 1 0.784314 rgBT /Overlo Psychiatry, 2021, 22, 561-628.	2.6	17
4	Prescription of St John's Wort extracts: clinical risks due to differences in their hyperforin content. Minerva Psychiatry, 2021, 62, .	0.3	0
5	Gerd Laux, Walter E. MÃ¼ller (Herausgeber): Psychopharmakologie und Psychopharmakotherapie kompakt. Weiterbildungs-Curriculum zum Facharzt fÃ¼r Psychiatrie und Psychotherapie. Swiss Archives of Neurology, Psychiatry and Psychotherapy, 2021, 172, .	0.1	0
6	The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 444-447.	2.5	1
7	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. Journal of Clinical Psychiatry, 2020, 81, .	2.2	86
8	4 Slow-drop infusion versus oral administration of citalopram: Comparison of plasma concentrations of the enantiomers of citalopram and its metabolites. , 2020, 53, .		0
9	Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers after Oral vs. Infusion Citalopram Therapy in Dextromethorphan- and Mephenytoin-Phenotyped Patients with Major Depression. Therapeutic Drug Monitoring, 2020, Publish Ahead of Print, 436-442.	2.0	1
10	Training in Psychopharmacology-Pharmacopsychiatry for Residents in Psychiatry. Mental Health and Illness Worldwide, 2019, , 141-167.	0.1	0
11	About the Misleading Use of Stereodescriptors in Labeling the Stereoisomers of Milnacipran and Levomilnacipran. Journal of Clinical Psychopharmacology, 2019, 39, 673-674.	1.4	0
12	Clinical Psychopharmacology in Switzerland. Journal of Clinical Psychopharmacology, 2019, 39, 5-8.	1.4	1
13	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World Journal of Biological Psychiatry, 2018, 19, 162-174.	2.6	103
14	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 2018, 51, 9-62.	3.3	787
15	Implementation of Therapeutic Drug Monitoring and Pharmacogenetic Tests in Psychiatry: How About ABCB1?. Journal of Bioequivalence & Bioavailability, 2018, 10, .	0.1	0
16	Training in Psychopharmacology-Pharmacopsychiatry for Residents in Psychiatry. Mental Health and Illness Worldwide, 2018, , 1-28.	0.1	0
17	A proposal for a psychopharmacologyâ€“pharmacotherapy catalogue of learning objectives and a curriculum in Europe. World Journal of Biological Psychiatry, 2017, 18, 29-38.	2.6	13
18	Age at the time of onset of psychosis: A marker of specific needs rather than a determinant of outcome?. European Psychiatry, 2017, 45, 20-26.	0.2	10

#	ARTICLE	IF	CITATIONS
19	Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT). Drug Metabolism and Personalized Therapy, 2017, 32, 173-174.	0.6	1
20	Clinical pharmacological management of polypharmacy in old age depression. European Psychiatry, 2016, 33, S39-S39.	0.2	0
21	Consensus guideline for therapeutic drug monitoring in psychiatry (2004): Bibliometric analysis of citations for the period 2004-2011. Nordic Journal of Psychiatry, 2016, 70, 202-207.	1.3	2
22	The AMSP-project: Pharmacovigilance in psychiatry - Presentation, challenges and results. European Psychiatry, 2014, 29, 663-663.	0.2	0
23	Pharmacovigilance en psychiatrie: donn�es r�centes. European Psychiatry, 2014, 29, 661-662.	0.2	0
24	A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. Journal of Affective Disorders, 2014, 168, 269-275.	4.1	90
25	Age and adverse drug reactions from psychopharmacological treatment: Data from the AMSP drug surveillance programme in Switzerland. Swiss Medical Weekly, 2013, 143, w13772.	1.6	13
26	Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression. Journal of Clinical Psychopharmacology, 2012, 32, 622-629.	1.4	26
27	Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. International Journal of Neuropsychopharmacology, 2012, 15, 1051-1061.	2.1	33
28	Cognitive Efficacy of Quetiapine in Early-Onset First-Episode Psychosis: A 12-Week Open Label Trial. Psychiatric Quarterly, 2012, 83, 311-324.	2.1	9
29	Flupentixol: relevance of stereoselective therapeutic drug monitoring. Psychopharmacology, 2012, 221, 719-720.	3.1	4
30	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring. , 2012, , 441-464.		6
31	Citation of the AGNP consensus guidelines for therapeutic drug monitoring in psychiatry 2004 in the scientific literature 2004 to 2011. Pharmacopsychiatry, 2012, 45, .	3.3	1
32	Clinical effectiveness, pharmacokinetics and pharmacogenetics of mirtazapine in depression. Pharmacopsychiatry, 2012, 45, .	3.3	0
33	Matched case-control study: therapeutic drug monitoring in pharmacovigilance. Pharmacopsychiatry, 2012, 45, .	3.3	0
34	Cytochrome <i>P450</i> and <i>ABCB1</i> genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. Journal of Psychopharmacology, 2011, 25, 896-907.	4.0	38
35	JS01-01 - Pharmacokinetics of psychotropic drugs - keys for treatments' improvements. European Psychiatry, 2011, 26, 1995-1995.	0.2	0
36	Therapeutic drug monitoring of drugs for treatment of substance-related disorders. European Psychiatry, 2011, 26, 13-13.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Ventajas y desventajas del tratamiento de combinaci3n con antipsic3ticos. Reuni3n ECNP Consensus, marzo de 2008, Niza. Psiquiatria Biologica, 2011, 18, 55-67.	0.1	2
38	Binding of Amitriptyline to $\hat{1}\pm$ 1-Acid Glycoprotein and its Variants. Journal of Pharmacy and Pharmacology, 2011, 40, 767-770.	2.4	22
39	Therapeutic Drug Monitoring for Drugs Used in the Treatment of Substance-Related Disorders: Literature Review Using a Therapeutic Drug Monitoring Appropriateness Rating Scale. Therapeutic Drug Monitoring, 2011, 33, 561-572.	2.0	25
40	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry, 2011, 44, 195-235.	3.3	774
41	Therapeutic Drug Monitoring in Psychiatry. Pharmacopsychiatry, 2011, 44, 193-194.	3.3	0
42	Quetiapine in Adolescents with Non-Affective Psychotic Disorders: An Open-Label Trial. Pharmacopsychiatry, 2011, 44, 87-95.	3.3	3
43	Quetiapine and Norquetiapine in Plasma and Cerebrospinal Fluid of Schizophrenic Patients Treated With Quetiapine. Journal of Clinical Psychopharmacology, 2010, 30, 496-503.	1.4	27
44	Interaction of psychotropic drugs with monoamine oxidase in rat brain. Journal of Pharmacy and Pharmacology, 2010, 53, 1125-1130.	2.4	12
45	Are Proper Names Rigid Designators?. Axiomathes, 2010, 20, 333-346.	0.6	2
46	French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs. Fundamental and Clinical Pharmacology, 2010, 24, 377-384.	1.9	11
47	SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents in the Drug Prescription Information. International Journal of Knowledge Discovery in Bioinformatics, 2010, 1, 1-11.	0.8	0
48	Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with<scp>l</scp>- and<scp>d</scp>,<scp>l</scp>-methadone. World Journal of Biological Psychiatry, 2010, 11, 390-399.	2.6	16
49	Cardiac Left Bundle Branch Block and Pancytopenia in Anorexia Nervosa: Higher Risk with Mirtazapine and Pantoprazole? Case Report. Pharmacopsychiatry, 2009, 42, 79-81.	3.3	16
50	Drug-induced Pisa syndrome under quetiapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1286-1287.	4.8	21
51	Therapeutic Drug Monitoring and Pharmacogenetic Tests in Pharmacovigilance - When and What?. European Psychiatry, 2009, 24, .	0.2	0
52	Steady-State Concentrations of Mirtazapine, N-Desmethyilmirtazapine, 8-Hydroxymirtazapine and their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, Age and Smoking Behaviour. Clinical Pharmacokinetics, 2009, 48, 63-70.	3.5	46
53	Advantages and disadvantages of combination treatment with antipsychotics. European Neuropsychopharmacology, 2009, 19, 520-532.	0.7	125
54	ABCB1 and Cytochrome P450 Polymorphisms. Journal of Clinical Psychopharmacology, 2009, 29, 319-326.	1.4	116

#	ARTICLE	IF	CITATIONS
55	Increased creatinine kinase and rhabdomyolysis in anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2008, 41, 766-767.	4.0	9
56	Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study. <i>Pharmacological Research</i> , 2008, 58, 344-347.	7.1	86
57	Pharmacovigilance in psychiatry: pharmacogenetic tests and therapeutic drug monitoring are promising tools. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 183-185.	3.1	3
58	Effect of the NMDA-Receptor Antagonist Dextromethorphan in Infant Rat Pneumococcal Meningitis. <i>Current Drug Metabolism</i> , 2008, 9, 83-88.	1.2	6
59	Concentrações plasmáticas de paroxetina em pacientes adultos e idosos com depressão. <i>Revista De Psiquiatria Do Rio Grande Do Sul</i> , 2008, 30, 13-18.	0.3	2
60	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring. , 2008, , 375-397.		1
61	Off-label Utilization of Antidepressants. <i>Acta Medica (Hradec Kralove)</i> , 2008, 51, 19-24.	0.5	1
62	Pharmacogenetics of Clozapine: In Vivo Role of Cytochrome P450 Isoforms and P-Glycoprotein. <i>Pharmacopsychiatry</i> , 2008, 41, .	3.3	0
63	Text Analysis and Drug Analysis: Therapeutic Drug Monitoring in the Prescription Information. <i>Pharmacopsychiatry</i> , 2008, 41, .	3.3	0
64	Metabolism of Psychotropic Drugs in the Human Brain: Significance for Therapeutic Drug Monitoring?. <i>Pharmacopsychiatry</i> , 2008, 41, .	3.3	0
65	The AGNP-TDM Expert Consensus Guidelines 2004: A Promising Start!. <i>Pharmacopsychiatry</i> , 2008, 41, .	3.3	0
66	TDMplus: The Combination of TDM, Check for Drug Interactions and Genotyping. <i>Pharmacopsychiatry</i> , 2008, 41, .	3.3	0
67	Purpura and ecchymosis under carbamazepine, chloral hydrate and melitracen-flupentixol. <i>European Journal of Dermatology</i> , 2008, 18, 103-4.	0.6	1
68	Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 123-128.	2.4	1
69	Value and Actuality of the Prescription Information for Therapeutic Drug Monitoring of Psychopharmaceuticals: A Comparison with the Medico-Scientific Evidence. <i>Pharmacopsychiatry</i> , 2007, 40, 121-127.	3.3	21
70	Selective Serotonin Reuptake Inhibitors in Adolescent Depression Still Controversial. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 325-326.	1.4	1
71	Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, S1-207.	2.1	55
72	Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?. <i>Physiology and Behavior</i> , 2007, 92, 226-231.	2.1	48

#	ARTICLE	IF	CITATIONS
73	Problem solving in psychopharmacotherapy using pharmacokinetic and pharmacogenetic tests. <i>European Psychiatry</i> , 2007, 22, S96.	0.2	0
74	Therapeutic drug monitoring of antidepressants – clinical aspects. , 2007, , 261-267.		14
75	Therapeutic drug monitoring of antidepressants–clinical aspects. <i>Journal of Neural Transmission Supplementum</i> , 2007, , 261-7.	0.5	0
76	Dose-Dependent Venlafaxine-Induced Hair Loss. <i>Drug Safety</i> , 2006, 29, 911-1010.	3.2	0
77	Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance. <i>Drug Safety</i> , 2006, 29, 735-768.	3.2	89
78	Prevalence of substance use in a Swiss psychiatric hospital: Interview reports and urine screening. <i>Addictive Behaviors</i> , 2006, 31, 1252-1258.	3.0	30
79	Clinical Relevance of TDM of SSRIs. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 716-717.	2.0	5
80	Epileptiform Seizure After Sertraline Treatment in an Adolescent Experiencing Obsessive-Compulsive Disorder and Presenting a Rare Pharmacogenetic Status. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 679-681.	1.4	14
81	Psychotropic drug prescriptions in hospitalized elderly psychiatric patients: comparison with adult psychiatric patients. <i>Psychogeriatrics</i> , 2006, 6, 68-73.	1.2	0
82	Adverse Drug Reactions Following Nonresponse in a Depressed Patient with CYP2D6 Deficiency and Low CYP 3A4/5 Activity. <i>Pharmacopsychiatry</i> , 2006, 39, 150-152.	3.3	17
83	Drug monographs on drugs which are frequently analysed in the context of Therapeutic Drug Monitoring / Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden. <i>Das Medizinische Laboratorium</i> , 2006, 30, 443-452.	0.0	0
84	Mirtazapine Enantiomers in Blood and Cerebrospinal Fluid. <i>Neuropsychobiology</i> , 2006, 54, 179-181.	1.9	6
85	Increased Clozapine Plasma Concentrations and Side Effects Induced by Smoking Cessation in 2 CYP1A2 Genotyped Patients. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 539-543.	2.0	84
86	Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 593-604.	4.7	208
87	Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 865-873.	1.9	70
88	Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. <i>Psychopharmacology</i> , 2005, 181, 751-760.	3.1	91
89	Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 403-410.	2.1	85
90	Treatment of suicide attempters prior to hospital admission. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 694-701.	4.8	1

#	ARTICLE	IF	CITATIONS
91	Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 952-956.	4.8	20
92	The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. <i>Dialogues in Clinical Neuroscience</i> , 2005, 7, 231-247.	3.7	50
93	Prescribing practices in German and Swiss psychiatric university and in non-university hospitals: national differences. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2005, 43, 339-349.	0.6	4
94	Clinical Relevance of Citalopram (CIT) Plasma and Cerebrospinal Fluid (CSF) Concentrations: Impact with CSF Monoamine Metabolites. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
95	Metabolism of Citalopram by MAO: Pharmacogenetic and Kinetic Animal Studies. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
96	Plasma-CSF Concentrations Relationship of Psychotropic Drugs. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
97	Follow-Up of a Pharmacovigilance Study in Psychiatry Involving TDM and Pharmacogenetic Testing. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
98	Severe Bruising as an Adverse Event: Chocolate or Fluvoxamine? Case Report. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
99	Optimisation of psychopharmacotherapy: Clinical relevance of pharmacogenetic tests and therapeutic drug monitoring. <i>Pharmacopsychiatry</i> , 2005, 38, .	3.3	0
100	Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. <i>Journal of Psychopharmacology</i> , 2004, 18, 559-566.	4.0	5
101	Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. <i>Journal of Psychopharmacology</i> , 2004, 18, 559-566.	4.0	24
102	The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry. <i>Pharmacopsychiatry</i> , 2004, 37, 243-265.	3.3	453
103	High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004, 8, 191-195.	2.4	7
104	Oral administration of a low dose of midazolam (75µg) as an in vivo probe for CYP3A activity. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 237-46.	1.9	89
105	Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 231-6.	1.9	82
106	Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 802, 339-345.	2.3	40
107	Determination of human plasma levels of levo- α -acetylmethadol and its metabolites by gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 805, 141-146.	2.3	2
108	Death following acute poisoning by moclobemide. <i>Forensic Science International</i> , 2004, 140, 101-107.	2.2	13

#	ARTICLE	IF	CITATIONS
109	Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 55-63.	4.7	57
110	Nonresponse to Clozapine and Ultrarapid CYP1A2 Activity. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 214-219.	1.4	104
111	High Dose of Depot Risperidone in a Nonresponder Schizophrenic Patient. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 673-674.	1.4	14
112	Chirality in the New Generation of Antidepressants. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 366-374.	2.0	35
113	Stereoselective Metabolism of Citalopram in Plasma and Cerebrospinal Fluid of Depressive Patients. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 283-290.	1.4	34
114	CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 255-260.	5.7	30
115	Therapeutic Monitoring of Antidepressants in the Era of Pharmacogenetics Studies. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 152-155.	2.0	24
116	Therapeutic Monitoring of Psychotropic Drugs. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 167-170.	2.0	42
117	Major depressive disorder in the general hospital: adaptation of clinical practice guidelines. <i>General Hospital Psychiatry</i> , 2003, 25, 185-193.	2.4	27
118	Identification of a novel splice-site mutation in the CYP1A2 gene. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 341-344.	2.4	53
119	Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. <i>Drug and Alcohol Dependence</i> , 2003, 69, 205-211.	3.2	42
120	Methadone Maintenance Treatment and St. John's Wort. <i>Pharmacopsychiatry</i> , 2003, 36, 35-37.	3.3	80
121	Clinical Outcome after Trimipramine in Patients with Delusional Depression - a Pilot Study. <i>Pharmacopsychiatry</i> , 2003, 36, 12-17.	3.3	31
122	Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 39-47.	5.7	87
123	Routine Therapeutic Drug Monitoring in Patients Treated with 10-360 mg/day Citalopram. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 600-608.	2.0	31
124	Influence of metabolic processes on course and treatment of opioid-dependence. <i>Pharmacopsychiatry</i> , 2003, 36, .	3.3	0
125	The Effect of Fluoxetine on the Pharmacokinetics and Safety of Risperidone in Psychotic Patients. <i>Pharmacopsychiatry</i> , 2002, 35, 50-56.	3.3	73
126	In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations. <i>Molecular Psychiatry</i> , 2002, 7, 181-188.	7.9	27

#	ARTICLE	IF	CITATIONS
127	Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. <i>International Clinical Psychopharmacology</i> , 2002, 17, 141-143.	1.7	116
128	Very Long Half-Life of Paroxetine Following Intoxication in an Extensive Cytochrome P4502D6 Metabolizer. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 567-569.	2.0	6
129	Paroxetine Increases Steady-State Concentrations of (R)-Methadone in CYP2D6 Extensive but Not Poor Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 211-215.	1.4	81
130	Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. <i>European Neuropsychopharmacology</i> , 2002, 12, 255-260.	0.7	51
131	Enantiomers' potential in psychopharmacology—a critical analysis with special emphasis on the antidepressant escitalopram. <i>European Neuropsychopharmacology</i> , 2002, 12, 433-444.	0.7	79
132	Interindividual Variability of the Clinical Pharmacokinetics of Methadone. <i>Clinical Pharmacokinetics</i> , 2002, 41, 1153-1193.	3.5	510
133	Pharmacogenetics of chiral psychotropic drugs. , 2002, , 181-214.		4
134	Therapy with Antidepressants: Pharmacogenetic Aspects. , 2002, 21, 95-111.		0
135	Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment. <i>Chirality</i> , 2002, 14, 347-350.	2.6	4
136	Clozapine is more efficacious for tongue dystonia than olanzapine. <i>Psychopharmacology</i> , 2002, 162, 89-89.	3.1	9
137	Pathologic Laughter Associated With Paroxetine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 231.	1.4	3
138	Pharmakokinetik und therapeutisches Monitoring von Antidepressiva. , 2002, , 37-50.		0
139	In vitro metabolism of citalopram by monoamine oxidase B in human blood. <i>European Neuropsychopharmacology</i> , 2001, 11, 75-78.	0.7	13
140	Lithium Augmentation in Venlafaxine-Refractory Depression. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 242-243.	1.4	5
141	Pharmacokinetic Drug Interaction Potential of Risperidone With Cytochrome P450 Isozymes as Assessed by the Dextromethorphan, the Caffeine, and the Mephenytoin Test. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 228-231.	2.0	29
142	Methadone Blood Concentrations Are Decreased by the Administration of Abacavir Plus Amprenavir. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 553-555.	2.0	59
143	Cytochrome P450 2D6 Genotype and Methadone Steady-State Concentrations. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 229-234.	1.4	102
144	Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 330-334.	1.4	57

#	ARTICLE	IF	CITATIONS
145	An alternative to interruption of treatment in recurrent clozapine-induced severe neutropenia. <i>British Journal of Psychiatry</i> , 2001, 179, 180-180.	2.8	29
146	Enantiomeric antidepressant drugs should be considered on individual merit. <i>Human Psychopharmacology</i> , 2001, 16, S85-S92.	1.5	25
147	Lithium Augmentation in Depressive Patients Not Responding to Selective Serotonin Reuptake Inhibitors. <i>Pharmacopsychiatry</i> , 2001, 34, 119-127.	3.3	43
148	Fluvoxamine and Perphenazine for Psychosis in Alzheimer's Disease: Pharmacokinetic Considerations. <i>Journal of Nervous and Mental Disease</i> , 2001, 189, 798-799.	1.0	2
149	Cytochrome P-450 activities in human and rat brain microsomes. <i>Brain Research</i> , 2000, 855, 235-243.	2.2	72
150	Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. <i>International Journal of Neuropsychopharmacology</i> , 2000, 3, 55-60.	2.1	19
151	Marked Increase of Venlafaxine Enantiomer Concentrations as a Consequence of Metabolic Interactions: A Case Report. <i>Pharmacopsychiatry</i> , 2000, 33, 112-115.	3.3	27
152	Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. <i>Drug and Alcohol Dependence</i> , 2000, 61, 47-54.	3.2	101
153	P02.271 Pharmacokinetic drug interaction potential of risperidone as assessed by the dextromethorphan, the caffeine and the mephenytoin test. <i>European Psychiatry</i> , 2000, 15, 394s-395s.	0.2	0
154	P01.174 Rapid remission of depression after carbamazepine augmentation of venlafaxine. <i>European Psychiatry</i> , 2000, 15, 367s-367s.	0.2	1
155	Efavirenz decreases methadone blood concentrations. <i>Aids</i> , 2000, 14, 1291.	2.2	50
156	Serotonin Syndrome After Small Doses of Citalopram or Sertraline. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 713-714.	1.4	17
157	Steady State Plasma Levels of the Enantiomers of Trimipramine and of Its Metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-Phenotyped Patients. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 209-214.	2.0	49
158	Inappropriate antidiuretic hormone secretion and rhabdomyolysis associated with citalopram. <i>Therapie</i> , 2000, 55, 651-2.	1.0	13
159	Psychotropic Drug Prescription in a Psychiatric University Hospital. <i>Pharmacopsychiatry</i> , 1999, 32, 29-37.	3.3	37
160	Olanzapine for mixed episodes of bipolar disorder. <i>Journal of Psychopharmacology</i> , 1999, 13, 198-198.	4.0	15
161	Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. <i>Brain Research</i> , 1999, 831, 229-236.	2.2	71
162	Oral and intravenous methadone use: some clinical and pharmacokinetic aspects. <i>Drug and Alcohol Dependence</i> , 1999, 55, 137-143.	3.2	19

#	ARTICLE	IF	CITATIONS
163	The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 55-60.	5.7	98
164	Effects of Carbamazepine Coadministration on Plasma Concentrations of the Enantiomers of Mianserin and of its Metabolites. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 166-170.	2.0	27
165	Pharmacokinetic Consequences of a Citalopram Treatment Discontinuation. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 263.	2.0	9
166	Stereoselective Biotransformation of the Selective Serotonin Reuptake Inhibitor Citalopram and Its Demethylated Metabolites by Monoamine Oxidases in Human Liver. <i>Biochemical Pharmacology</i> , 1998, 56, 15-23.	4.4	83
167	A double-blind double-dummy study of citalopram comparing infusion versus oral administration. <i>Journal of Affective Disorders</i> , 1998, 49, 203-210.	4.1	29
168	Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. <i>Biomedical Applications</i> , 1998, 719, 234-238.	1.7	65
169	Simultaneous Determination of Human Plasma Levels of Citalopram, Paroxetine, Sertraline, and Their Metabolites by Gas Chromatography–Mass Spectrometry. <i>Journal of Chromatographic Science</i> , 1998, 36, 365-371.	1.4	105
170	Correspondence. <i>Clinica Chimica Acta</i> , 1998, 271, 105-107.	1.1	0
171	An automated procedure for the determination of protein concentration in subcellular fractions. <i>Clinica Chimica Acta</i> , 1998, 273, 89-93.	1.1	2
172	The serotonin paradox: Negative symptoms and SSRI augmentation. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998, 2, 19-26.	2.4	13
173	Ultrarapid Metabolism of Clomipramine in a Therapy-Resistant Depressive Patient, as Confirmed by CYP2D6 Genotyping. <i>Pharmacopsychiatry</i> , 1998, 31, 72-72.	3.3	21
174	Risperidone Versus Clozapine in Treatment-Resistant Chronic Schizophrenia: A Randomized Double-Blind Study. <i>American Journal of Psychiatry</i> , 1998, 155, 499-504.	7.2	266
175	Care of depression in the elderly. <i>International Clinical Psychopharmacology</i> , 1998, 13, S35-S44.	1.7	22
176	Characteristics of Psychotropic Drug Metabolism in Geriatric Patients. , 1998, 13, 159-170.		1
177	High Interindividual Variability of Methadone Enantiomer Blood Levels to Dose Ratios. <i>Archives of General Psychiatry</i> , 1998, 55, 89.	12.3	55
178	Steady State Concentrations of the Enantiomers of Mianserin and Desmethylmianserin in Poor and in Homozygous and Heterozygous Extensive Metabolizers of Debrisoquine. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 7-13.	2.0	22
179	The Effect of the N-methyl-D-aspartate Receptor Antagonist Dextromethorphan on Perioperative Brain Injury in Children Undergoing Cardiac Surgery with Cardiopulmonary Bypass: Results of a Pilot Study. <i>Neuropediatrics</i> , 1997, 28, 191-197.	0.6	21
180	Determination of the Enantiomers of Mianserin and its Metabolites in Plasma by Capillary Electrophoresis After Liquid–Liquid Extraction and On-Column Sample Preconcentration. <i>Journal of Chromatographic Science</i> , 1997, 35, 315-320.	1.4	24

#	ARTICLE	IF	CITATIONS
181	Long-term treatment of depression. <i>International Clinical Psychopharmacology</i> , 1997, 12, 77-80.	1.7	8
182	Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 1-10.	5.7	112
183	S.03.01 Advantages and disadvantages of lithium augmentation. <i>European Neuropsychopharmacology</i> , 1997, 7, S82.	0.7	0
184	P.1.010 MAO-A and MAO-B differ in their stereoselective biotransformation of citalopram in human liver. <i>European Neuropsychopharmacology</i> , 1997, 7, S137-S138.	0.7	0
185	ANTIDEPRESSANT TREATMENT BEFORE HOSPITALIZATION FOR MAJOR DEPRESSION: OFTEN PRESCRIBED, OFTEN UNDERTITRATED. <i>Pharmacological Research</i> , 1997, 35, 33-36.	7.1	3
186	THE ASSOCIATION CARBAMAZEPINE-MIANSERIN IN OPIATE WITHDRAWAL: A DOUBLE BLIND PILOT STUDY VERSUS CLONIDINE. <i>Pharmacological Research</i> , 1997, 35, 451-456.	7.1	31
187	Fluvoxamine and Fluoxetine Do Not Interact in the Same Way With the Metabolism of the Enantiomers of Methadone. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 113-117.	1.4	68
188	Treatment-resistant schizophrenia: clinical experience with new antipsychotics. <i>European Neuropsychopharmacology</i> , 1996, 6, 21-25.	0.7	33
189	Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 1996, 50, 385-389.	1.9	87
190	Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors???. <i>Clinical Pharmacokinetics</i> , 1996, 31, 444-469.	3.5	182
191	Inappropriate secretion of antidiuretic hormone and SSRIs. <i>British Journal of Psychiatry</i> , 1996, 169, 524-525.	2.8	21
192	Pharmacology and pharmacokinetics of citalopram and other SSRIs. <i>International Clinical Psychopharmacology</i> , 1996, 11, 5-12.	1.7	88
193	Neuroendocrine Effects of a 20-mg Citalopram Infusion in Healthy Males A Placebo-Controlled Evaluation of Citalopram as 5-HT Function Probe. <i>Neuropsychopharmacology</i> , 1996, 14, 253-263.	5.4	97
194	Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. <i>Psychopharmacology</i> , 1996, 128, 421-425.	3.1	66
195	Caffeine consumption in hospitalized psychiatric patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1996, 246, 83-92.	3.2	62
196	Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , 1996, 682, 265-272.	1.7	76
197	Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 322-331.	4.7	61
198	Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. <i>Biomedical Applications</i> , 1996, 686, 51-63.	1.7	76

#	ARTICLE	IF	CITATIONS
199	Pharmacokinetic Fluvoxamine - Clomipramine Interaction with Favorable Therapeutic Consequences in Therapy-resistant Depressive Patient. <i>Pharmacopsychiatry</i> , 1996, 29, 108-110.	3.3	38
200	A Double-Blind, Placebo-Controlled Study of Citalopram With and Without Lithium in the Treatment of Therapy-Resistant Depressive Patients. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 307-314.	1.4	156
201	Fluoxetine Addition to Methadone in Addicts: Pharmacokinetic Aspects. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 570-572.	2.0	32
202	Comparative pharmacokinetics of selective serotonin reuptake inhibitors. <i>International Clinical Psychopharmacology</i> , 1995, 10, 15-22.	1.7	88
203	Analysis of Enantiomers of Citalopram and Its Demethylated Metabolites in Plasma of Depressive Patients Using Chiral Reverse-Phase Liquid Chromatography. <i>Therapeutic Drug Monitoring</i> , 1995, 17, 273-279.	2.0	125
204	Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. <i>Chirality</i> , 1995, 7, 389-395.	2.6	75
205	Citalopram-lithium combination treatment of elderly depressed patients: A pilot study. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 281-287.	2.7	20
206	Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. <i>Biomedical Applications</i> , 1995, 669, 271-279.	1.7	38
207	Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: A case report. <i>Biological Psychiatry</i> , 1995, 38, 404-406.	1.3	4
208	Reversible neutropenia during a cold: possible involvement of risperidone? A case report. <i>European Neuropsychopharmacology</i> , 1995, 5, 1-2.	0.7	12
209	Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. <i>Pharmacological Research</i> , 1995, 31, 347-353.	7.1	66
210	Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 333-339.	1.9	34
211	Determination of the enantiomers of mianserin, desmethylmianserin, and 8-hydroxymianserin in the plasma and urine of mianserin-treated patients. <i>Chirality</i> , 1994, 6, 555-563.	2.6	20
212	Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry.. <i>Biomedical Applications</i> , 1994, 652, 97-103.	1.7	9
213	Levomepromazine a substrate of cytochrome CYP2D6?. <i>European Neuropsychopharmacology</i> , 1994, 4, 370.	0.7	0
214	Increased trimipramine plasma levels during fluvoxamine comedication. <i>European Neuropsychopharmacology</i> , 1994, 4, 15-20.	0.7	32
215	Influence of amesergide treatment on the dextromethorphan test [letter]. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 151-152.	2.4	1
216	Probable Metabolic Interaction Between Methadone and Fluvoxamine in Addict Patients. <i>Therapeutic Drug Monitoring</i> , 1994, 16, 42-45.	2.0	74

#	ARTICLE	IF	CITATIONS
217	Determination of plasma levels of citalopram and its demethylated and deaminated metabolites by gas chromatography and gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , 1993, 616, 221-228.	1.7	38
218	Artifacts in the analysis of thioridazine and other neuroleptics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1993, 11, 451-457.	2.8	20
219	Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. <i>European Journal of Clinical Pharmacology</i> , 1993, 44, 403-405.	1.9	30
220	Orosomuroid System: 17 Additional Orosomuroid Variants and Proposal for a New Nomenclature. <i>Vox Sanguinis</i> , 1993, 64, 47-55.	1.5	42
221	Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropic drugs. <i>Nordic Journal of Psychiatry</i> , 1993, 47, 13-19.	1.3	14
222	Orosomuroid System: 17 Additional Orosomuroid Variants and Proposal for a New Nomenclature. <i>Vox Sanguinis</i> , 1993, 64, 47-55.	1.5	24
223	Genetischer Polymorphismus des Metabolismus von Neuroleptika: klinische Relevanz?. , 1993, , 99-110.		1
224	Pharmakokinetische und pharmakodynamische Interaktionen zwischen trizyklischen und serotonergen Antidepressiva im Verlauf einer Behandlung. , 1993, , 664-670.		0
225	Klinische Relevanz pharmakogenetischer Phänotypisierungen. , 1993, , 658-663.		0
226	CITALOPRAM IN ELDERLY DEPRESSED PATIENTS AND ADJUNCTIVE LITHIUM IN NON-RESPONDERS. <i>Clinical Neuropharmacology</i> , 1992, 15, 339B.	0.7	1
227	Plasma Levels of Trimipramine and Metabolites in Four Patients. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 380-385.	2.0	20
228	Dextromethorphan and Mephenytoin Phenotyping of Patients Treated with Thioridazine or Amitriptyline. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 1-8.	2.0	68
229	Influence of Quinidine on the Pharmacokinetics of Trimipramine and on Its Effect on the Waking EEG of Healthy Volunteers. <i>Neuropsychobiology</i> , 1992, 25, 214-220.	1.9	16
230	Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 350-358.	4.7	94
231	Alopecia and mood stabilizers: Two case reports. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992, 242, 85-88.	3.2	9
232	Allgemeine Grundlagen der Pharmakokinetik und Pharmakodynamik. , 1992, , 273-286.		0
233	Variations in relative concentrations of variants of human α_1 -acid glycoprotein after acute-phase conditions. <i>Clinica Chimica Acta</i> , 1991, 203, 379-385.	1.1	31
234	Clozapine as an alternative treatment for neuroleptic-induced gynecomastia. <i>American Journal of Psychiatry</i> , 1991, 148, 392a-393.	7.2	4

#	ARTICLE	IF	CITATIONS
235	Light-Induced Racemization. Therapeutic Drug Monitoring, 1991, 13, 356-362.	2.0	18
236	Inflammation-induced changes in expression and glycosylation of genetic variants of α 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice. Biochemical Journal, 1991, 276, 343-347.	3.7	48
237	Use of Plasma Level Monitoring of Antidepressants in Clinical Practice. Pharmacopsychiatry, 1991, 24, 190-195.	3.3	42
238	Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: Role of the variants of α 1-acid glycoprotein. Clinical Pharmacology and Therapeutics, 1990, 47, 338-346.	4.7	125
239	Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. European Journal of Clinical Pharmacology, 1990, 39, 613-614.	1.9	66
240	Pharmakokinetische Aspekte der Therapieresistenz mit Antidepressiva. , 1990, , 85-98.		5
241	Treatment of Endogenous Depressions Resistant to Tricyclic Antidepressants or Related Drugs by Lithium Addition. Results of a Placebo-Controlled Double-Blind Study. Pharmacopsychiatry, 1989, 22, 183-187.	3.3	85
242	Use of transgenic mice for the characterization of human α 1-acid glycoprotein (orosomuroid) variants. Human Genetics, 1989, 84, 89-91.	3.8	38
243	Isoelectric focusing of α -1 acid glycoprotein (orosomuroid) in immobilized pH-gradients with 8M urea: Detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. Electrophoresis, 1988, 9, 650-654.	2.4	45
244	Orosomuroid (α -1 acid glycoprotein) phenotyping by use of immobilized pH gradients with 8M urea and immunoblotting. Human Genetics, 1988, 80, 183-185.	3.8	30
245	Selectivity in the binding of psychotropic drugs to the variants of α -1 acid glycoprotein. Naunyn-Schmiedeberg's Archives of Pharmacology, 1988, 337, 220-4.	3.0	24
246	GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin. Clinica Chimica Acta, 1988, 171, 211-222.	1.1	44
247	Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities. Pharmacopsychiatry, 1988, 21, 285-287.	3.3	9
248	New Aspects in Research on Blood Levels and Bioavailability of Antidepressants. Psychopathology, 1986, 19, 79-84.	1.5	6
249	Amitriptyline Pharmacokinetics and Clinical Response: I. Free and Total Plasma Amitriptyline and Nortriptyline. International Clinical Psychopharmacology, 1986, 1, 89-101.	1.7	20
250	Amitriptyline Pharmacokinetics and Clinical Response: II. Metabolic Polymorphism Assessed by Hydroxylation of Debrisoquine and Mephenytoin. International Clinical Psychopharmacology, 1986, 1, 102-112.	1.7	55
251	Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of α 1-acid glycoprotein. European Journal of Clinical Pharmacology, 1985, 27, 661-666.	1.9	49
252	Hydroxylated Metabolites of Amitriptyline in Rat Brain After Repeated Administration of the Parent Drug. Pharmacopsychiatry, 1985, 18, 91-93.	3.3	2

#	ARTICLE	IF	CITATIONS
253	Transport Systems and Enzymes Involved in the Metamorphosis of Tryptophan into Serotonin. <i>Pharmacopsychiatry</i> , 1985, 18, 188-192.	3.3	5
254	N-methylation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients. <i>Biochemical Pharmacology</i> , 1985, 34, 409-410.	4.4	17
255	Determination of compliance with riboflavin in an antidepressive therapy. <i>Arzneimittelforschung</i> , 1985, 35, 536-8.	0.4	0
256	Evaluation of the levels of free and total amitriptyline and metabolites in the plasma and brain of the rat after long-term administration of doses used in receptor studies. <i>Psychopharmacology</i> , 1984, 84, 489-495.	3.1	28
257	Amitriptylinmetabolismus im depressiven Patienten: Pharmakogenetische Aspekte und EiweiÃbindung im Plasma. , 1984, , 298-305.		2
258	Relationships between brain concentrations of desipramine and paradoxical sleep inhibition in the rat. <i>Journal of Neural Transmission</i> , 1983, 56, 105-116.	2.8	23
259	The fate of amitriptyline and its metabolites, taking into account their binding in plasma. , 1983, , 227-237.		1
260	Quality Control of Amitriptyline and Nortriptyline Plasma Level Assessments. <i>Pharmacopsychiatry</i> , 1982, 15, 156-160.	3.3	5
261	Increase of alpha 1âacid glycoprotein after treatment with amitriptyline.. <i>British Journal of Clinical Pharmacology</i> , 1982, 14, 102-103.	2.4	27
262	On the Relationship between Free Plasma and Saliva Amitriptyline and Nortriptyline. <i>International Pharmacopsychiatry</i> , 1982, 17, 136-146.	0.4	16
263	Microprocedure to determine the polymorphic forms of acid 1-glycoprotein in plasma. <i>Biomedical Applications</i> , 1982, 229, 319-325.	1.7	12
264	Effects of Chronic Neuroleptic Therapy on Human PRL Secretion and Testicular Function. <i>Archives of Andrology</i> , 1981, 6, 219-228.	1.0	2
265	Relationship between Plasma-levels of Chlorpromazine and Effects on EEG and Evoked Potentials in Healthy Volunteers. <i>Pharmacopsychiatry</i> , 1981, 14, 199-204.	3.3	11
266	Effect of calcitonin on free and total plasma tryptophan in human. <i>Acta Vitaminologica Et Enzymologica</i> , 1980, 2, 6-8.	0.1	0
267	Distribution of Tryptophan in Erythrocytes, Leukocytes and Thrombocytes, and Its Binding to Plasma Albumin. , 1979, , 165-176.		3
268	The Influence of Oral Tryptophan on Cortical Evoked Responses in Normals and Schizophrenics. , 1979, , 177-188.		1
269	Neuroendocrine effects of chronic neuroleptic therapy in male psychiatric patients. <i>Psychoneuroendocrinology</i> , 1978, 3, 245-252.	2.7	14
270	Lithium concentrations in saliva, plasma and red blood cells of patients given lithium acetate. <i>Acta Psychiatrica Scandinavica</i> , 1978, 58, 67-79.	4.5	19

#	ARTICLE	IF	CITATIONS
271	The analysis of free tryptophan in human blood with the ultrafiltrator: A comparison with other methods. <i>Clinica Chimica Acta</i> , 1977, 76, 223-231.	1.1	20
272	Insulin coma therapy: Decrease of plasma tryptophan in man. <i>Journal of Neural Transmission</i> , 1976, 39, 309-313.	2.8	4
273	Micro-determination of SiO ₂ , TiO ₂ , total iron (Fe ₂ O ₃), P ₂ O ₅ and F in silicates by automatic solution photometry. <i>Fresenius Zeitschrift für Analytische Chemie</i> , 1975, 277, 359-368.	0.8	9
274	Metabolism of 5-hydroxytryptophan-14c after intracisternal injection with and without the influence of drugs in the rat brain. <i>Psychopharmacology</i> , 1975, 45, 39-45.	3.1	4
275	Quantitative determination of indolic compounds in the rat brain using p-dimethylaminocinnamaldehyde as reagent. <i>Journal of Chromatography A</i> , 1975, 109, 313-324.	3.7	7
276	Free and bound tryptophan in the blood of depressives. <i>Acta Vitaminologica Et Enzymologica</i> , 1975, 29, 255-61.	0.1	1
277	Determination of free and bound plasma tryptophan by ultrafiltration. <i>Clinica Chimica Acta</i> , 1974, 51, 35-40.	1.1	19
278	Identification of N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine and bufotenin by cellulose TLC. <i>Journal of Chromatography A</i> , 1973, 86, 269-273.	3.7	14
279	Influence of Progesterone on Norepinephrine Metabolism of the Rat Brain in Connection with Amphetamine and Stress. <i>Neuroendocrinology</i> , 1971, 7, 16-24.	2.5	7
280	Separation of indole derivatives and catecholamines by thin-layer chromatography. <i>Journal of Chromatography A</i> , 1971, 59, 463-466.	3.7	13
281	Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with l- and d,l-methadone. <i>World Journal of Biological Psychiatry</i> , 0, , 1-10.	2.6	4
282	SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents. , 0, , 319-328.		0